Clinical Trial

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-01-05; most recent amendment 2026-02-10.
Trial Details
NCT Number NCT05197270
Lead Sponsor 4D Molecular Therapeutics
Conditions Neovascular (Wet) Age-Related Macular Degeneration
Enrollment 215 participants
Start Date 2021-12-09
Primary Completion 2027-03 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-12